RESUMEN
BACKGROUND: There have been multiple reforms in South Africa to conserve resources including policies to enhance generic use, such as compulsory generic substitution and copayments. However, there are concerns with the limited knowledge of their impact. OBJECTIVE: The objective was to determine utilization and expenditure of different proton pump inhibitors (PPIs). METHODOLOGY: A retrospective drug utilization study was conducted on a prescription database of a medical aid administrator in 2010. RESULTS: The limited prescribing of single-sourced PPIs accounted for 21.5% of total prescriptions. The limited use of originators omeprazole and lansoprazole accounted for 1.8 and 1.4% of total prescriptions for the molecule, respectively. Generic prices accounted for 36-68% of the originator in 2010. Patients received on average 2.91 PPI prescriptions during the year. CONCLUSION: Policies to enhance prescribing of generics appear working. Opportunities exist to further lower generic prices given low prices in some European countries.
Asunto(s)
Medicamentos Genéricos/provisión & distribución , Pautas de la Práctica en Medicina/estadística & datos numéricos , Inhibidores de la Bomba de Protones/provisión & distribución , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Medicamentos Genéricos/economía , Femenino , Humanos , Lactante , Recién Nacido , Lansoprazol/economía , Lansoprazol/provisión & distribución , Masculino , Persona de Mediana Edad , Omeprazol/economía , Omeprazol/provisión & distribución , Pautas de la Práctica en Medicina/economía , Sector Privado/estadística & datos numéricos , Inhibidores de la Bomba de Protones/economía , Estudios Retrospectivos , Sudáfrica , Adulto JovenRESUMEN
BACKGROUND: Multiple reforms have recently been introduced in The Netherlands to improve prescribing efficiency. These include preference pricing policies for multiple sourced products, guidelines, and quality and efficiency targets, as well as regular pharmacotherapy meetings. OBJECTIVES: Assess the influence of these multiple measures on prescribing efficiency. METHODS: Retrospective observational study of all reimbursed prescriptions for proton pump inhibitors and statins between 2000 and 2010 using the Genees-en hulpmiddelen Informatie Project (Health Insurance) database. Utilization measured in defined daily doses. Narrative review of reforms. RESULTS: Reimbursed expenditure for the proton pump inhibitors fell by 58% in 2010 versus 2000 despite a threefold increase in utilization, helped by increasing utilization of generic omeprazole at only 2% of the prepatent loss price in 2010. Similarly, reimbursed expenditure for the statins fell by 14% in 2010 versus 2000 despite a 3.8-fold increase in utilization. Again, this was helped by increasing utilization of generic simvastatin at only 2% of the prepatent loss originator price. CONCLUSION: Multiple supply and demand measures, including the preference pricing policy, appear to have appreciably enhanced proton pump inhibitor and statin prescribing efficiency, providing examples to other countries.